Logo image of MRUS

MERUS NV (MRUS) Stock Overview

USA - NASDAQ:MRUS - NL0011606264 - Common Stock

69.19 USD
+0.97 (+1.42%)
Last: 9/22/2025, 8:47:07 PM
69.19 USD
0 (0%)
After Hours: 9/22/2025, 8:47:07 PM

MRUS Key Statistics, Chart & Performance

Key Statistics
52 Week High70.65
52 Week Low33.19
Market Cap5.23B
Shares75.63M
Float73.18M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-5.54
PEN/A
Fwd PEN/A
Earnings (Next)10-29 2025-10-29/amc
IPO05-19 2016-05-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


MRUS short term performance overview.The bars show the price performance of MRUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

MRUS long term performance overview.The bars show the price performance of MRUS in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of MRUS is 69.19 USD. In the past month the price increased by 2.52%. In the past year, price increased by 44.93%.

MERUS NV / MRUS Daily stock chart

MRUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.02 393.22B
AMGN AMGEN INC 13.11 153.97B
GILD GILEAD SCIENCES INC 14.53 139.58B
VRTX VERTEX PHARMACEUTICALS INC 22.62 98.23B
REGN REGENERON PHARMACEUTICALS 13.05 63.14B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.16B
ARGX ARGENX SE - ADR 79.83 45.29B
ONC BEONE MEDICINES LTD-ADR 5.9 40.16B
INSM INSMED INC N/A 30.65B
NTRA NATERA INC N/A 24.59B
BNTX BIONTECH SE-ADR N/A 23.73B
BIIB BIOGEN INC 8.79 20.62B

About MRUS

Company Profile

MRUS logo image Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 260 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.

Company Info

MERUS NV

Yalelaan 62

Utrecht UTRECHT 3584 NL

CEO: Sven A. Lundberg

Employees: 291

MRUS Company Website

MRUS Investor Relations

Phone: 310302538800

MERUS NV / MRUS FAQ

What is the stock price of MERUS NV today?

The current stock price of MRUS is 69.19 USD. The price increased by 1.42% in the last trading session.


What is the ticker symbol for MERUS NV stock?

The exchange symbol of MERUS NV is MRUS and it is listed on the Nasdaq exchange.


On which exchange is MRUS stock listed?

MRUS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MERUS NV stock?

25 analysts have analysed MRUS and the average price target is 93.36 USD. This implies a price increase of 34.93% is expected in the next year compared to the current price of 69.19. Check the MERUS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MERUS NV worth?

MERUS NV (MRUS) has a market capitalization of 5.23B USD. This makes MRUS a Mid Cap stock.


How many employees does MERUS NV have?

MERUS NV (MRUS) currently has 291 employees.


What are the support and resistance levels for MERUS NV (MRUS) stock?

MERUS NV (MRUS) has a support level at 68.46 and a resistance level at 69.58. Check the full technical report for a detailed analysis of MRUS support and resistance levels.


Is MERUS NV (MRUS) expected to grow?

The Revenue of MERUS NV (MRUS) is expected to grow by 36.58% in the next year. Check the estimates tab for more information on the MRUS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MERUS NV (MRUS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MERUS NV (MRUS) stock pay dividends?

MRUS does not pay a dividend.


When does MERUS NV (MRUS) report earnings?

MERUS NV (MRUS) will report earnings on 2025-10-29, after the market close.


What is the Price/Earnings (PE) ratio of MERUS NV (MRUS)?

MERUS NV (MRUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.54).


What is the Short Interest ratio of MERUS NV (MRUS) stock?

The outstanding short interest for MERUS NV (MRUS) is 5.96% of its float. Check the ownership tab for more information on the MRUS short interest.


MRUS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to MRUS. When comparing the yearly performance of all stocks, MRUS is one of the better performing stocks in the market, outperforming 88.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MRUS Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to MRUS. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRUS Financial Highlights

Over the last trailing twelve months MRUS reported a non-GAAP Earnings per Share(EPS) of -5.54. The EPS decreased by -93.03% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -39.33%
ROE -45.8%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-175.31%
Sales Q2Q%20.4%
EPS 1Y (TTM)-93.03%
Revenue 1Y (TTM)59.78%

MRUS Forecast & Estimates

25 analysts have analysed MRUS and the average price target is 93.36 USD. This implies a price increase of 34.93% is expected in the next year compared to the current price of 69.19.

For the next year, analysts expect an EPS growth of -83.55% and a revenue growth 36.58% for MRUS


Analysts
Analysts87.2
Price Target93.36 (34.93%)
EPS Next Y-83.55%
Revenue Next Year36.58%

MRUS Ownership

Ownership
Inst Owners97.7%
Ins Owners0.38%
Short Float %5.96%
Short Ratio6.71